- Trials with a EudraCT protocol (273)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
273 result(s) found for: MDD AND Major Depressive Disorder.
Displaying page 1 of 14.
| EudraCT Number: 2006-005578-39 | Sponsor Protocol Number: PKI108574 | Start Date*: 2007-01-18 | |||||||||||
| Sponsor Name:GlaxoSmithKline | |||||||||||||
| Full Title: A randomised, double-blind, placebo-controlled study to explore the antidepressant properties of the P38a kinase inhibitor GW856553X 15mg compared to placebo in subjects with Major Depressive Disor... | |||||||||||||
| Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: EE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-008280-96 | Sponsor Protocol Number: EMC | Start Date*: 2009-08-10 | ||||||||||||||||||||||||||
| Sponsor Name:Department of Psychiatry and Psychotherapy, University of Mainz | ||||||||||||||||||||||||||||
| Full Title: Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial. | ||||||||||||||||||||||||||||
| Medical condition: Major Depressive disorder (MDD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2007-002740-16 | Sponsor Protocol Number: ME1-1 | Start Date*: 2007-08-23 | |||||||||||
| Sponsor Name:M's Science Corporation | |||||||||||||
| Full Title: A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment with SA4503, 1 mg or 3 mg Once Daily for 8 Weeks, in S... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) EE (Completed) LT (Completed) LV (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-001950-25 | Sponsor Protocol Number: VLZ-MD-02 | Start Date*: 2013-03-06 | ||||||||||||||||||||||||||
| Sponsor Name:Forest Research Institute, Inc., a wholly owned subsidiary of Forest Laboratories, Inc. | ||||||||||||||||||||||||||||
| Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder | ||||||||||||||||||||||||||||
| Medical condition: Major Depressive Disorder | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) FI (Completed) BG (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-022257-41 | Sponsor Protocol Number: Lu AA21004/CCT-002 | Start Date*: 2010-12-07 | ||||||||||||||||
| Sponsor Name:Takeda Global Research and Development Centre (Europe) Ltd. | ||||||||||||||||||
| Full Title: A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder | ||||||||||||||||||
| Medical condition: major depressive disorder (MDD) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: LV (Completed) DE (Completed) FI (Completed) RO (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-024198-38 | Sponsor Protocol Number: 13267B | Start Date*: 2011-03-04 | ||||||||||||||||
| Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||
| Full Title: A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder | ||||||||||||||||||
| Medical condition: Major Depressive Disorder | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FI (Completed) BE (Completed) SE (Completed) EE (Completed) LV (Completed) LT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2014-000379-14 | Sponsor Protocol Number: ALK5461-207 | Start Date*: 2014-11-10 | |||||||||||
| Sponsor Name:Alkermes, Inc. | |||||||||||||
| Full Title: A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study) | |||||||||||||
| Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2024-000604-29 | Sponsor Protocol Number: VENL-CAZ-3001 | Start Date*: 2026-03-17 | |||||||||||
| Sponsor Name:Viatris Pharmaceutical Japan GK | |||||||||||||
| Full Title: A placebo-controlled, randomized, double-blind, multicenter study to evaluate the efficacy and safety of venlafaxine in Japanese pediatric outpatients with Major Depressive Disorder (MDD) or Persis... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) or Persistent Depressive Disorder (PDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004208-20 | Sponsor Protocol Number: GH001-MDD-102 | Start Date*: 2019-08-21 | |||||||||||||||||||||
| Sponsor Name:Gh Research Limited | |||||||||||||||||||||||
| Full Title: A phase 1/2 study of GH001 in patients with treatment-resistant depression | |||||||||||||||||||||||
| Medical condition: Treatment-resistant depression | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2022-000439-22 | Sponsor Protocol Number: 67953964MDD3001_VENTURA-1 | Start Date*: 2023-03-08 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) CZ (Completed) ES (Ongoing) HU (Completed) BE (Completed) BG (Completed) PT (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-006800-34 | Sponsor Protocol Number: RONIN | Start Date*: 2022-03-31 | ||||||||||||||||
| Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | ||||||||||||||||||
| Full Title: The Role of Negr1 In modulating Neuroplasticity in major depression | ||||||||||||||||||
| Medical condition: patients with major depression | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2024-000605-33 | Sponsor Protocol Number: VENL-CAZ-3002 | Start Date*: 2026-03-17 | |||||||||||
| Sponsor Name:Viatris Pharmaceutical Japan GK | |||||||||||||
| Full Title: An open-label, long-term extension, multicenter study to evaluate the safety and efficacy of venlafaxine in Japanese pediatric outpatients with Major Depressive Disorder (MDD) or Persistent Depress... | |||||||||||||
| Medical condition: Major Depressive Disorder (MDD) or Persistent Depressive Disorder (PDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001529-24 | Sponsor Protocol Number: 190-062 | Start Date*: 2007-03-06 | |||||||||||
| Sponsor Name:Sepracor NV in care of Sepracor Inc. | |||||||||||||
| Full Title: Adults adminstered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered with Venlafaxine in Subjects wit... | |||||||||||||
| Medical condition: Insomnia Major Depressive Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) AT (Completed) SE (Completed) GB (Completed) FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-002160-24 | Sponsor Protocol Number: BP25712 | Start Date*: 2012-04-12 | ||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd. | ||||||||||||||||||
| Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major D... | ||||||||||||||||||
| Medical condition: Major Depressive Disorder | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Completed) DE (Completed) SK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-002362-21 | Sponsor Protocol Number: 14178A | Start Date*: 2011-11-15 | |||||||||||
| Sponsor Name:H. Lundbeck A/S | |||||||||||||
| Full Title: A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder... | |||||||||||||
| Medical condition: -Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) EE (Completed) CZ (Completed) LT (Completed) DE (Completed) ES (Completed) PL (Completed) AT (Completed) BG (Completed) GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-004169-42 | Sponsor Protocol Number: 14767B | Start Date*: 2013-08-14 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Major Depressive Disorder | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: SE (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-017523-26 | Sponsor Protocol Number: 13267A | Start Date*: 2010-05-11 | ||||||||||||||||
| Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||
| Full Title: A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of... | ||||||||||||||||||
| Medical condition: Major Depressive Disorder | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FI (Completed) SE (Completed) DE (Completed) EE (Completed) SK (Completed) LV (Completed) LT (Completed) BE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2017-004030-28 | Sponsor Protocol Number: EKFADHTC01032017 | Start Date*: 2018-09-10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Psychiatric Research Unit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cognition and weight gain during antidepressant treatment. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Major Depressive Disorder. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2010-021044-17 | Sponsor Protocol Number: CLOCK_depression | Start Date*: 2010-08-11 | |||||||||||
| Sponsor Name:Medizinische Universität Wien | |||||||||||||
| Full Title: The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study. | |||||||||||||
| Medical condition: Major depressive disorder (MDD), Seasonal affective disorder (subtype of MDD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-011795-29 | Sponsor Protocol Number: CL3-20098-070 | Start Date*: 2009-09-04 | |||||||||||
| Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
| Full Title: Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomised, double-blind, flexible-dose, parallel gr... | |||||||||||||
| Medical condition: Major Depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) PT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.